DNA Script
Transforming how molecular biology translates to human health, personalized medicine, and synthetic biology.
- biotechnology
- horizon europe
- dt and ls
- spinout
- radar de l'innovation
- tech for business
- observatoire industrial tech
- genetics and genomics
- observatoire deeptech
- dna
- genome engineering
- biotech, medtech and e-health
- tech for biotech and pharma
- observatoire healthtech
- synthetic biology
- digital pharma
- precision medicine
- participations bpifrance
- french tech 2030
- enzymes
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $35.0m Valuation: $825m | Series C | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 10199 % | 68 % | 183 % | 59 % | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (42551 %) | (537 %) | (702 %) | (561 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (38476 %) | (512 %) | (759 %) | (598 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
DNA Script revolutionizes DNA synthesis with its proprietary enzymatic technology. The company has developed SYNTAX™️, the world's first benchtop DNA printer, which integrates innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. DNA Script serves clients in genomics research and personalized medicine, providing a cutting-edge tool that simplifies and accelerates DNA synthesis. Operating in the biotechnology market, the company generates revenue through the sale of its SYNTAX™️ system and related consumables. By enabling rapid and efficient DNA synthesis, DNA Script aims to drive advancements in genomics and personalized healthcare.
Keywords: DNA synthesis, enzymatic technology, benchtop printer, genomics research, personalized medicine, enzyme engineering, nucleotide chemistries, biotechnology, SYNTAX system, healthcare.